Anavex (AVXL) Life Sciences announced the latest findings for blarcamesine, an oral small molecule for the potential treatment of early Alzheimer’s disease, AD. On all standard scales for measuring Alzheimer’s disease and cognitive decline, after 48 weeks, the defined Precision Medicine population ABCLEAR31 consisting of early AD patients with confirmed and progressed pathology taking 30 mg once-daily oral blarcamesine demonstrated barely detectable decline. This was comparable to minimally perceptible decline in prodromal aging adults. For ADAS-Cog13, blarcamesine showed a 48-week change from baseline of 0.853 compared to ~1 point typical annual decline in prodromal aging adults. For CDR-SB, blarcamesine demonstrated a change from baseline of 0.465, aligning with the 0-0.5 point annual range seen in prodromal aging.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVXL:
- Anavex Life Sciences Earnings Call: Promising Alzheimer’s Progress Amid Operational Challenges
- Largest borrow rate increases among liquid names
- Anavex reports new publication on mechanism with blarcamesine
- Anavex announces new publication on blarcamesine in Alzheimer’s
- Anavex Life Sciences: Navigating Legal Risks and Regulatory Challenges in a High-Stakes Industry